1/27/2012 7:59:39 AM
Two of the scientific founders of a couple of Seattle’s best-funded biotech startups have come together in a new company that aims to create a valuable antibody drug candidates while burning through the least amount of venture capital possible. The new Seattle-based company, called V-Gene, is being started by combining a couple of technologies developed by Johnny Stine and Steve Wiley. Stine is the founder of Theraclone Sciences (formerly Spaltudaq), and Wiley is the co-founder of VLST, a pair of companies founded at Accelerator. The new startup has gotten a term sheet for an initial $1.2 million in financing from an undisclosed venture investor, Stine says, and although the deal isn’t signed yet, he expects that round to close before the end of March.
comments powered by